Association of near-infrared spectroscopy-defined lipid rich plaque with lesion morphology and peri-coronary inflammation on computed tomography angiography.


Journal

Atherosclerosis
ISSN: 1879-1484
Titre abrégé: Atherosclerosis
Pays: Ireland
ID NLM: 0242543

Informations de publication

Date de publication:
04 2022
Historique:
received: 04 08 2021
revised: 24 12 2021
accepted: 14 01 2022
pubmed: 5 2 2022
medline: 6 5 2022
entrez: 4 2 2022
Statut: ppublish

Résumé

Recent studies have reported that the lipid-rich plaque (LRP) detected by near-infrared spectroscopy (NIRS) and the pericoronary adipose tissue attenuation (PCATA) evaluated by coronary computed tomography angiography (CCTA) are associated with worse outcomes. We sought to investigate the relationship between NIRS-defined LRP and PCATA or the incremental ability of PCATA for the prediction of the presence of NIRS-defined LRP when added to the CCTA-derived morphometric findings. A total of 101 de novo lesions of 101 patients with chronic coronary syndromes (CCS), who underwent pre-procedural CCTA and NIRS during percutaneous coronary intervention (PCI), were retrospectively studied. PCATA was assessed by the crude analysis of the mean CT attenuation value of the culprit vessel. NIRS-defined LRP was defined as a maximum lipid core burden index in 4 mm ≥ 400. Univariate and multivariate logistic regression analyses were performed to determine the predictors of NIRS-defined LRP. NIRS-defined LRP was observed in 37 patients and median PCATA was -72.71. A significant relationship was observed between LCBI and PCATA (r = 0.24, p = 0.001). PCATA (OR: 4.99; 95% CI: 1.48-16.82; p = 0.010) and CCTA-derived positive remodeling (OR: 12.53; 95% CI: 3.56-44.07; p < 0.001) were independent predictors of NIRS-defined LRP. Net reclassification and integrated discrimination improvement indices were both significantly improved when PCATA was added to the reference model including clinical characteristics and CCTA-derived morphometric findings. Comprehensive assessment of CCTA including PCATA may provide reliable information to identify the presence of NIRS-defined LRP potentially leading to future adverse events after PCI.

Sections du résumé

BACKGROUND AND AIMS
Recent studies have reported that the lipid-rich plaque (LRP) detected by near-infrared spectroscopy (NIRS) and the pericoronary adipose tissue attenuation (PCATA) evaluated by coronary computed tomography angiography (CCTA) are associated with worse outcomes. We sought to investigate the relationship between NIRS-defined LRP and PCATA or the incremental ability of PCATA for the prediction of the presence of NIRS-defined LRP when added to the CCTA-derived morphometric findings.
METHODS
A total of 101 de novo lesions of 101 patients with chronic coronary syndromes (CCS), who underwent pre-procedural CCTA and NIRS during percutaneous coronary intervention (PCI), were retrospectively studied. PCATA was assessed by the crude analysis of the mean CT attenuation value of the culprit vessel. NIRS-defined LRP was defined as a maximum lipid core burden index in 4 mm ≥ 400. Univariate and multivariate logistic regression analyses were performed to determine the predictors of NIRS-defined LRP.
RESULTS
NIRS-defined LRP was observed in 37 patients and median PCATA was -72.71. A significant relationship was observed between LCBI and PCATA (r = 0.24, p = 0.001). PCATA (OR: 4.99; 95% CI: 1.48-16.82; p = 0.010) and CCTA-derived positive remodeling (OR: 12.53; 95% CI: 3.56-44.07; p < 0.001) were independent predictors of NIRS-defined LRP. Net reclassification and integrated discrimination improvement indices were both significantly improved when PCATA was added to the reference model including clinical characteristics and CCTA-derived morphometric findings.
CONCLUSIONS
Comprehensive assessment of CCTA including PCATA may provide reliable information to identify the presence of NIRS-defined LRP potentially leading to future adverse events after PCI.

Identifiants

pubmed: 35115160
pii: S0021-9150(22)00024-7
doi: 10.1016/j.atherosclerosis.2022.01.010
pii:
doi:

Substances chimiques

Lipids 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

109-116

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2022 Elsevier B.V. All rights reserved.

Auteurs

Masao Yamaguchi (M)

Division of Cardiovascular Medicine, Tsuchiura Kyodo General Hospital, Ibaraki, Japan.

Masahiro Hoshino (M)

Division of Cardiovascular Medicine, Tsuchiura Kyodo General Hospital, Ibaraki, Japan.

Tomoyo Sugiyama (T)

Division of Cardiovascular Medicine, Tsuchiura Kyodo General Hospital, Ibaraki, Japan.

Yoshihisa Kanaji (Y)

Division of Cardiovascular Medicine, Tsuchiura Kyodo General Hospital, Ibaraki, Japan.

Tatsuhiro Nagamine (T)

Division of Cardiovascular Medicine, Tsuchiura Kyodo General Hospital, Ibaraki, Japan.

Toru Misawa (T)

Division of Cardiovascular Medicine, Tsuchiura Kyodo General Hospital, Ibaraki, Japan.

Masahiro Hada (M)

Division of Cardiovascular Medicine, Tsuchiura Kyodo General Hospital, Ibaraki, Japan.

Makoto Araki (M)

Division of Cardiovascular Medicine, Tsuchiura Kyodo General Hospital, Ibaraki, Japan.

Rikuta Hamaya (R)

Division of Cardiovascular Medicine, Tsuchiura Kyodo General Hospital, Ibaraki, Japan.

Eisuke Usui (E)

Division of Cardiovascular Medicine, Tsuchiura Kyodo General Hospital, Ibaraki, Japan.

Tadashi Murai (T)

Division of Cardiovascular Medicine, Tsuchiura Kyodo General Hospital, Ibaraki, Japan.

Tetsumin Lee (T)

Division of Cardiovascular Medicine, Tsuchiura Kyodo General Hospital, Ibaraki, Japan.

Taishi Yonetsu (T)

Department of Cardiovascular Medicine, Tokyo Medical and Dental University, Tokyo, Japan.

Tetsuo Sasano (T)

Department of Cardiovascular Medicine, Tokyo Medical and Dental University, Tokyo, Japan.

Tsunekazu Kakuta (T)

Division of Cardiovascular Medicine, Tsuchiura Kyodo General Hospital, Ibaraki, Japan. Electronic address: kaz@joy.email.ne.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH